A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression

Cancer Cell

Volumn 20, Issue 2, 2011, Pages 214-228

  Yuan, Wei Chien ^a,b   Lee, Yu Ru ^a,c   Huang, Shiu Feng ^d,e   Lin, Yu Min ^a,b   Chen, Tzu Yin ^a,b   Chung, Hsiang Ching ^a,b   Tsai, Chin Hsien ^b,f   Chen, Hsin Yi ^a   Chiang, Cheng Ta ^a,b   Lai, Chun Kai ^a,b   Lu, Li Ting ^a,b   Chen, Chun Hau ^g   Gu, De Leung ^h,i   Pu, Yeong Shiau ^j   Jou, Yuh Shan ^h   Lu, Kun Ping ^g   Hsiao, Pei Wen ^f   Shih, Hsiu Ming ^h   Chen, Ruey Hwa ^a,b,c  

^a INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f AGRICULTURAL BIOTECHNOLOGY RESEARCH CENTER   (Taiwan)

^g HARVARD MEDICAL SCHOOL   (United States)

^h INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

ⁱ NATIONAL YANG MING UNIVERSITY   (Taiwan)

^j NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN 3; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PEPTIDYLPROLYL ISOMERASE PIN1; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KLHL20; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; ISOMERIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UBIQUITINATION; UPREGULATION;

EID: 80051583598     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.07.008     Document Type: Article

References (36)

1. Bernardi R., Pandolfi P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 2007, 8:1006-1016.
2. Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M.C., Rafii S., Pandolfi P.P. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 2006, 442:779-785.
3. Brahimi-Horn M.C., Chiche J., Pouysségur J. Hypoxia and cancer. J. Mol. Med. 2007, 85:1301-1307.
4. Condemine W., Takahashi Y., Zhu J., Puvion-Dutilleul F., Guegan S., Janin A., de Thé H. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res. 2006, 66:6192-6198.
5. de Thé H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990, 347:558-561.
6. de Thé H., Lavau C., Marchio A., Chomienne C., Degos L., Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
7. Dellaire G., Ching R.W., Dehghani H., Ren Y., Bazett-Jones D.P. The number of PML nuclear bodies increases in early S phase by a fission mechanism. J. Cell Sci. 2006, 119:1026-1033.
8. Fanelli M., Fantozzi A., De Luca P., Caprodossi S., Matsuzawa S., Lazar M.A., Pelicci P.G., Minucci S. The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J. Biol. Chem. 2004, 279:5374-5379.
9. Finger E.C., Giaccia A.J. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010, 29:285-293.
10. Gurrieri C., Capodieci P., Bernardi R., Scaglioni P.P., Nafa K., Rush L.J., Verbel D.A., Cordon-Cardo C., Pandolfi P.P. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J. Natl. Cancer Inst. 2004, 96:269-279.
11. Henze A.T., Acker T. Feedback regulators of hypoxia-inducible factors and their role in cancer biology. Cell Cycle 2010, 9:2749-2763.
12. Huang Y., Du K.M., Xue Z.H., Yan H., Li D., Liu W., Chen Z., Zhao Q., Tong J.H., Zhu Y.S., Chen G.Q. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia 2003, 17:2065-2073.
13. Ishov A.M., Sotnikov A.G., Negorev D., Vladimirova O.V., Neff N., Kamitani T., Yeh E.T., Strauss J.F., Maul G.G. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 1999, 147:221-234.
14. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., Peres L., Berthier C., Soilihi H., Raught B., de Thé H. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010, 18:88-98.
15. Lallemand-Breitenbach V., Zhu J., Puvion F., Koken M., Honoré N., Doubeikovsky A., Duprez E., Pandolfi P.P., Puvion E., Freemont P., de Thé H. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J. Exp. Med. 2001, 193:1361-1371.
16. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B., de Thé H. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 2008, 10:547-555.
17. Lee Y.R., Yuan W.C., Ho H.C., Chen C.H., Shih H.M., Chen R.H. The Cullin 3 substrate adaptor KLHL20 mediates DAPK ubiquitination to control interferon responses. EMBO J. 2010, 29:1748-1761.
18. Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., Ho C.C., Chen Y.C., Lin T.P., Fang H.I., et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 2006, 24:341-354.
19. Liu W., Guo M., Xu Y.B., Li D., Zhou Z.N., Wu Y.L., Chen Z., Kogan S.C., Chen G.Q. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood 2006, 107:698-707.
20. Louria-Hayon I., Alsheich-Bartok O., Levav-Cohen Y., Silberman I., Berger M., Grossman T., Matentzoglu K., Jiang Y.H., Muller S., Scheffner M., et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ. 2009, 16:1156-1166.
21. Lu K.P., Hanes S.D., Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996, 380:544-547.
22. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
23. Melnick A., Licht J.D. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999, 93:3167-3215.
24. Nacak T.G., Alajati A., Leptien K., Fulda C., Weber H., Miki T., Czepluch F.S., Waltenberger J., Wieland T., Augustin H.G., Kroll J. The BTB-Kelch protein KLEIP controls endothelial migration and sprouting angiogenesis. Circ. Res. 2007, 100:1155-1163.
25. Pintard L., Willems A., Peter M. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J. 2004, 23:1681-1687.
26. Reineke E.L., Lam M., Liu Q., Liu Y., Stanya K.J., Chang K.S., Means A.R., Kao H.Y. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol. Cell. Biol. 2008, 28:997-1006.
27. Reineke E.L., Liu Y., Kao H.Y. Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J. Biol. Chem. 2010, 285:9485-9492.
28. Salomoni P., Pandolfi P.P. The role of PML in tumor suppression. Cell 2002, 108:165-170.
29. Salomoni P., Ferguson B.J., Wyllie A.H., Rich T. New insights into the role of PML in tumour suppression. Cell Res. 2008, 18:622-640.
30. Scaglioni P.P., Yung T.M., Cai L.F., Erdjument-Bromage H., Kaufman A.J., Singh B., Teruya-Feldstein J., Tempst P., Pandolfi P.P. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006, 126:269-283.
31. Semenza G.L. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29:625-634.
32. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 2008, 10:538-546.
33. Trotman L.C., Alimonti A., Scaglioni P.P., Koutcher J.A., Cordon-Cardo C., Pandolfi P.P. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 2006, 441:523-527.
34. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 1995, 92:5510-5514.
35. Wang Z.G., Delva L., Gaboli M., Rivi R., Giorgio M., Cordon-Cardo C., Grosveld F., Pandolfi P.P. Role of PML in cell growth and the retinoic acid pathway. Science 1998, 279:1547-1551.
36. Zhou X.Z., Kops O., Werner A., Lu P.J., Shen M., Stoller G., Küllertz G., Stark M., Fischer G., Lu K.P. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 2000, 6:873-883.